Dow Jones

39,448.31

-0.16%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

ALT

Altimmune (ALT)

Altimmune Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALT

1 2 3 4 5 6 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
10/05/2024	04:45	PR Newswire (US)	The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders	NASDAQ:ALT	Altimmune Inc
09/05/2024	16:51	PR Newswire (US)	INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm	NASDAQ:ALT	Altimmune Inc
09/05/2024	15:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALT	Altimmune Inc
09/05/2024	06:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALT	Altimmune Inc
09/05/2024	06:00	GlobeNewswire Inc.	Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update	NASDAQ:ALT	Altimmune Inc
07/05/2024	06:30	GlobeNewswire Inc.	Altimmune to Participate at Two Upcoming Investor Conferences	NASDAQ:ALT	Altimmune Inc
02/05/2024	06:30	GlobeNewswire Inc.	Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	NASDAQ:ALT	Altimmune Inc
01/05/2024	06:30	GlobeNewswire Inc.	Altimmune to Participate at Two Upcoming Conferences	NASDAQ:ALT	Altimmune Inc
25/04/2024	16:24	GlobeNewswire Inc.	Altimmune Statement on the Passing of Dr. Stephen Harrison	NASDAQ:ALT	Altimmune Inc
27/03/2024	06:00	GlobeNewswire Inc.	Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:ALT	Altimmune Inc
27/03/2024	05:57	IH Market News	U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading	NASDAQ:ALT	Altimmune Inc
20/03/2024	06:30	GlobeNewswire Inc.	Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024	NASDAQ:ALT	Altimmune Inc
14/02/2024	11:04	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ALT	Altimmune Inc
05/02/2024	17:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALT	Altimmune Inc
26/01/2024	10:49	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ALT	Altimmune Inc
02/01/2024	06:30	GlobeNewswire Inc.	Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024	NASDAQ:ALT	Altimmune Inc
08/12/2023	07:35	GlobeNewswire Inc.	Water Tower Research US Climate Virtual Investor Conference: Presentations Now Available for Online Viewing	NASDAQ:ALT	Altimmune Inc
04/12/2023	07:35	GlobeNewswire Inc.	Water Tower Research US Climate Investor Conference Agenda Announced for December 7th, 2023	NASDAQ:ALT	Altimmune Inc
30/11/2023	15:24	GlobeNewswire Inc.	Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide	NASDAQ:ALT	Altimmune Inc
07/11/2023	06:00	GlobeNewswire Inc.	Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update	NASDAQ:ALT	Altimmune Inc
31/10/2023	06:30	GlobeNewswire Inc.	Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023	NASDAQ:ALT	Altimmune Inc
26/10/2023	07:15	Dow Jones News	Altimmune Gets FDA Fast-Track Designation for Pemvidutide in NASH	NASDAQ:ALT	Altimmune Inc
26/10/2023	06:30	GlobeNewswire Inc.	Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)	NASDAQ:ALT	Altimmune Inc
25/10/2023	06:30	GlobeNewswire Inc.	Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023	NASDAQ:ALT	Altimmune Inc
26/09/2023	06:30	GlobeNewswire Inc.	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes	NASDAQ:ALT	Altimmune Inc
12/09/2023	06:30	GlobeNewswire Inc.	Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight	NASDAQ:ALT	Altimmune Inc
16/08/2023	15:14	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ALT	Altimmune Inc
16/08/2023	15:10	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ALT	Altimmune Inc
10/08/2023	06:00	GlobeNewswire Inc.	Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update	NASDAQ:ALT	Altimmune Inc
03/08/2023	06:30	GlobeNewswire Inc.	Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023	NASDAQ:ALT	Altimmune Inc